MADISON, Wis.--(BUSINESS WIRE)--Nimble Therapeutics Inc. today announced the company has entered into a strategic collaboration with Incyte (NASDAQ: INCY) to discover first-in-class peptide therapies across various disease areas.
“This is an important collaboration for both companies to discover novel peptide based therapeutics,” said Jigar Patel, Ph.D., CEO of Nimble Therapeutics. “We are excited to partner with Incyte, an organization with world-class drug discovery, development and commercialization capabilities, to ensure maximal patient impact across multiple disease indications.”
The collaboration will leverage Nimble’s proprietary peptide synthesis, screening and optimization platform, coupled with its high chemical diversity and integrated suite of assays to enable faster discovery and optimization of promising compounds for intracellular and extracellular targets.
Under the terms of the agreement, Nimble will receive an undisclosed upfront payment, reimbursement of certain research program costs and may become eligible for downstream milestone payments and royalties. Incyte has exclusive rights to develop and commercialize any peptides discovered under the collaboration, and an option to further expand the collaboration to include additional targets.
About Nimble Therapeutics
Nimble Therapeutics is bringing the power of parallel chemical synthesis to drug discovery. Nimble’s proprietary technology enables the rapid synthesis, screening and engineering of millions of scaffolded natural and modified macrocyclic peptidomimetics. Nimble has also developed a variety of biological assays that aid in the empirical screening and optimization of molecules with more favorable drug-like properties. The company is developing partnerships with leading pharmaceutical companies to leverage its technology across many therapeutic areas. For more information please see www.nimbletherapeutics.com.
